How a breast cancer pioneer finally turned a profit

October 18, 2012

First-mover advantage is no guarantee of early success. Myriad Genetics, which makes diagnostic tests to detect predisposition to cancers, burned through more than $500 million over 17 years before turning a profit. (Forbes)